Marinus Pharmaceuticals
Search

Managed Access Program

Marinus is dedicated to developing new therapies for patients with rare seizure disorders, and to serving patients, their families and the healthcare professionals who care for them.

Consistent with our mission to bring innovative medicines to patients with serious or life-threatening conditions, we are focused on conducting the clinical trials necessary to gain regulatory approvals to make our medicines available broadly to patients as quickly as possible. Clinical trials are an essential part of collecting the necessary data on safety and efficacy to support regulatory approval. At the same time, we understand that there are patients who will not be eligible for our clinical trials and for whom there are limited options for alternative therapies.

In such circumstances, Marinus offers the Marinus Access Program for eligible patients with seizures associated with CDKL5 deficiency disorder

About the Marinus Access Program

The Marinus Access Program enables physicians to request ZTALMY® (ganaxolone) oral suspension CV for eligible patients with seizures associated with CDKL5 deficiency disorder in geographies where the product is not commercially available and as supported by local regulatory requirements. The program does not provide free of charge access to ZTALMY and does not affect patients already taking ZTALMY as part of a clinical trial. The Marinus Access Program is managed by Durbin, a leader in the international distribution of specialized pharmaceuticals.

Access requests in geographies where Marinus has a commercial arrangement in place are managed by the local commercial organization and are not eligible for the Marinus Access Program:

  • Algeria, Bahrain, Egypt, Iraq, Jordan, Kingdom of Saudi Arabia, Kuwait, Lebanon, Libya, Morocco, Oman, Qatar, Tunisia, and United Arab Emirates: Biologix FZco
  • Mainland China, the Hong Kong Special Administrative Region, Macau Special Administrative Region, and Taiwan: Tenacia Biotechnology Co., Ltd.

Physicians can learn more about the Marinus Access Program for ZTALMY by sending an email to MarinusMAP@durbinglobal.com.